CytomX Therapeutics, Inc. (NASDAQ:CTMX) Director Frederick W. Gluck sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $25.01, for a total value of $250,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
CytomX Therapeutics, Inc. (CTMX) opened at $24.92 on Wednesday. CytomX Therapeutics, Inc. has a 52-week low of $10.64 and a 52-week high of $25.60. The stock has a market capitalization of $957.14 and a P/E ratio of -15.87.
Large investors have recently made changes to their positions in the company. Legal & General Group Plc lifted its position in shares of CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 1,434 shares in the last quarter. Macquarie Group Ltd. purchased a new position in shares of CytomX Therapeutics during the 3rd quarter valued at approximately $107,000. Cubist Systematic Strategies LLC purchased a new position in shares of CytomX Therapeutics during the 2nd quarter valued at approximately $174,000. Voya Investment Management LLC purchased a new position in shares of CytomX Therapeutics during the 2nd quarter valued at approximately $203,000. Finally, Nationwide Fund Advisors lifted its position in shares of CytomX Therapeutics by 39.4% during the 2nd quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock valued at $254,000 after buying an additional 4,622 shares in the last quarter. Hedge funds and other institutional investors own 63.13% of the company’s stock.
Several research firms have commented on CTMX. BidaskClub upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, December 15th. Cowen restated an “outperform” rating on shares of CytomX Therapeutics in a research report on Thursday, October 5th. Oppenheimer restated a “hold” rating on shares of CytomX Therapeutics in a research report on Wednesday, October 4th. Wedbush set a $37.00 price objective on CytomX Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 4th. Finally, Cantor Fitzgerald began coverage on CytomX Therapeutics in a research report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company’s stock. CytomX Therapeutics presently has an average rating of “Buy” and an average price target of $32.78.
ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/10/frederick-w-gluck-sells-10000-shares-of-cytomx-therapeutics-inc-ctmx-stock.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.